Marshall Wace’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Marshall Wace’s Portfolio GRTS Stock Details GRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-422,045	Closed	-$1.17M	–	3093
2023 Q1	$1.17M	Buy	422,045 +175,719	+71%	+$502K	﹤0.01%	1734
2022 Q4	$850K	Buy	246,326 +212,710	+633%	+$607K	﹤0.01%	2156
2022 Q3	$87K	Sell	33,616 -80,418	-71%	-$256K	﹤0.01%	3203
2022 Q2	$276K	Sell	114,034 -200,349	-64%	-$526K	﹤0.01%	3067
2022 Q1	$1.29M	Buy	+314,383	New	+$1.67M	﹤0.01%	2327
2021 Q4	–	Sell	-27,074	Closed	-$292K	–	4372
2021 Q3	$292K	Sell	27,074 -62,210	-70%	-$566K	﹤0.01%	2658
2021 Q2	$815K	Sell	89,284 -7,767	-8%	-$71.8K	﹤0.01%	1909
2021 Q1	$915K	Buy	+97,051	New	+$1.34M	﹤0.01%	1707
2020 Q2	–	Sell	-4,689	Closed	-$27K	–	2027
2020 Q1	$27K	Buy	+4,689	New	+$39.4K	﹤0.01%	1499
2019 Q4	–	Sell	-149,643	Closed	-$1.29M	–	2148
2019 Q3	$1.29M	Sell	149,643 -123,191	-45%	-$1.24M	0.01%	878
2019 Q2	$3.04M	Buy	272,834 +164,815	+153%	+$1.88M	0.03%	647
2019 Q1	$1.44M	Buy	+108,019	New	+$1.44M	0.01%	833

Other funds holding GRTS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's GRTS Position: Q2 2023 in Review

Marshall Wace sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q2 2023, closing a stake of 422,045 shares — an estimated $1.17M sold.

Marshall Wace first reported a position in GRTS in Q1 2019 and held it in 12 quarters. The position peaked at $3.04M in Q2 2019. 88 funds tracked by Wall St. Rank hold GRTS as of Q2 2023.

Marshall Wace reported no remaining Gritstone bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Marshall Wace sold 422,045 Gritstone bio, Inc. Common Stock shares in Q2 2023, an estimated $1.17M.
Marshall Wace first reported a position in Gritstone bio, Inc. Common Stock in Q1 2019 and held it in 12 quarters.
Marshall Wace's Gritstone bio, Inc. Common Stock position peaked at $3.04M in Q2 2019.
88 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.